54.19
price down icon1.45%   -0.80
after-market Dopo l'orario di chiusura: 54.19
loading
Precedente Chiudi:
$54.99
Aprire:
$53.15
Volume 24 ore:
764.86K
Relative Volume:
0.89
Capitalizzazione di mercato:
$3.36B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
20.68
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
-4.33%
1M Prestazione:
+1.56%
6M Prestazione:
+43.36%
1 anno Prestazione:
+41.67%
Intervallo 1D:
Value
$53.02
$54.50
Intervallo di 1 settimana:
Value
$53.02
$57.73
Portata 52W:
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
Nome
Protagonist Therapeutics Inc
Name
Telefono
(510) 474-0170
Name
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
Dipendente
124
Name
Cinguettio
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
PTGX's Discussions on Twitter

Confronta PTGX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
54.19 3.41B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-17 Iniziato Citigroup Buy
2024-12-06 Iniziato BMO Capital Markets Outperform
2024-12-06 Iniziato Goldman Neutral
2024-11-05 Iniziato Wedbush Outperform
2024-09-24 Iniziato TD Cowen Buy
2024-09-09 Iniziato Truist Buy
2023-10-30 Iniziato CapitalOne Overweight
2023-05-25 Ripresa Jefferies Buy
2022-08-25 Iniziato JMP Securities Mkt Outperform
2022-02-11 Iniziato BTIG Research Buy
2021-10-12 Aggiornamento JP Morgan Neutral → Overweight
2021-10-11 Aggiornamento Northland Capital Market Perform → Outperform
2021-09-20 Downgrade JP Morgan Overweight → Neutral
2021-05-24 Iniziato JMP Securities Mkt Outperform
2021-05-24 Iniziato Northland Capital Outperform
2021-01-06 Iniziato JP Morgan Overweight
2020-12-16 Iniziato Piper Sandler Overweight
2020-09-18 Reiterato H.C. Wainwright Buy
2020-07-15 Iniziato Jefferies Buy
2020-05-18 Reiterato H.C. Wainwright Buy
2019-07-08 Iniziato H.C. Wainwright Buy
2019-05-09 Aggiornamento Stifel Hold → Buy
2018-12-06 Iniziato Nomura Buy
2018-01-29 Iniziato Stifel Buy
2017-07-21 Iniziato BTIG Research Buy
Mostra tutto

Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie

pulisher
Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025
pulisher
Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025
pulisher
Jul 17, 2025

How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 15, 2025

How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛

Jul 12, 2025
pulisher
Jul 02, 2025

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech

Jul 02, 2025
pulisher
Jul 01, 2025

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com

Jul 01, 2025
pulisher
Jun 30, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman

Jun 30, 2025
pulisher
Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus

Jun 26, 2025
pulisher
Jun 24, 2025

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance

Jun 24, 2025
pulisher
Jun 20, 2025

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance

Jun 20, 2025
pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025

Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):